Breadcrumb Home Studies Studies Search Filter Research Area AllComplications & ComorbiditiesCureTreatmentTuberculosis Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentParticipants Off Study and Primary Analysis CompletedPending Sort Study Number AscStudy Number Desc Submit Search Showing 18 studies. IMPAACT 2047: Radiant-Moms Plus DAIDS Number TBD Research Area Tuberculosis Study Status In Development IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Therapeutics Study Status Enrolling IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status In Development IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings DAIDS Number 38506 Research Area Brain and Mental Health Study Status Closed to Accrual P1110: Safety and PK of RAL in Neonates DAIDS Number 11891 Research Area Treatment Study Status Concluded P1100: AERAS 402 DAIDS Number 11801 Research Area Tuberculosis Study Status Concluded P1097: Raltegravir PK Study DAIDS Number 11790 Research Area Treatment Study Status Concluded P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed P1090: Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine DAIDS Number 10850 Research Area Treatment Study Status Concluded Pagination Current page 1 Page 2 Next page Next
IMPAACT 2047: Radiant-Moms Plus DAIDS Number TBD Research Area Tuberculosis Study Status In Development
IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Therapeutics Study Status Enrolling
IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status In Development
IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings DAIDS Number 38506 Research Area Brain and Mental Health Study Status Closed to Accrual
P1110: Safety and PK of RAL in Neonates DAIDS Number 11891 Research Area Treatment Study Status Concluded
P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
P1090: Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine DAIDS Number 10850 Research Area Treatment Study Status Concluded
